Kv3 Channel Modulators with Heterocyclic Rings
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for alternative modulators of Kv3.1, Kv3.2, Kv3.3, and Kv3.4 channels that demonstrate high in vivo potency, channel selectivity, improved safety profiles, and desirable pharmacokinetic parameters, such as high brain availability and low clearance rates, to effectively treat conditions like progressive myoclonic epilepsy, hearing disorders, schizophrenia, and pain, while offering distinct metabolites and balanced modulatory effects on these channels.
Innovation Solution
The development of a compound of formula (I), which includes specific heterocyclic and phenyl ring structures, acts as a modulator of Kv3 channels, potentially providing enhanced therapeutic effects by altering channel gating kinetics and inactivation properties, and can be administered as a medicament for various neurological disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing Kv3 channel modulators are used, then therapeutic effects are achieved, but in vivo potency and safety profiles are insufficient
Solution Approach 1:
The patent modifies molecular parameters of Kv3 channel modulators by introducing specific heterocyclic structures (pyridine, pyrimidine, triazine rings) and substituent groups (halogens, alkyl, alkoxy) to optimize the balance between therapeutic efficacy and safety profile, achieving improved in vivo potency with reduced harmful effects
Solution Approach 2:
The patent introduces localized functional groups at specific positions on the molecular structure (e.g., R1-R6 substituents on heterocyclic rings) to enhance channel selectivity and modulatory precision, thereby improving therapeutic effects while minimizing off-target harmful effects
2Reliability
If higher doses are administered to achieve therapeutic effect, then efficacy improves, but clearance rates increase and safety deteriorates
Solution Approach 1:
The patent optimizes pharmacokinetic parameters by modifying molecular weight, lipophilicity, and metabolic stability through strategic selection of heterocyclic cores and substituents, achieving prolonged duration of action at lower doses with reduced clearance rates
3Reliability
If channel selectivity is increased to improve therapeutic specificity, then off-target effects reduce, but development complexity increases
Solution Approach 1:
The patent achieves channel selectivity by introducing specific functional groups at defined positions on the heterocyclic scaffold (e.g., R3-R6 on pyrimidine/triazine rings), allowing precise modulation of Kv3.1/Kv3.2/Kv3.3/Kv3.4 channels while maintaining reasonable structural complexity for drug development
Data Source
AI summary
Ion channel modulator compounds of the formula: (Formula (I)), and related aspects.